Ocular Historical Balance Sheet
OCUL Stock | USD 9.44 0.09 0.96% |
Trend analysis of Ocular Therapeutix balance sheet accounts such as Total Current Liabilities of 36.6 M provides information on Ocular Therapeutix's total assets, liabilities, and equity, which is the actual value of Ocular Therapeutix to its prevalent stockholders. By breaking down trends over time using Ocular Therapeutix balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Ocular Therapeutix latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ocular Therapeutix is a good buy for the upcoming year.
Ocular Therapeutix Inventory |
|
Ocular |
About Ocular Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Ocular Therapeutix at a specified time, usually calculated after every quarter, six months, or one year. Ocular Therapeutix Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ocular Therapeutix and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ocular currently owns. An asset can also be divided into two categories, current and non-current.
Ocular Therapeutix Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Ocular Therapeutix assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ocular Therapeutix books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Ocular Therapeutix balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ocular Therapeutix are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Ocular Therapeutix's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ocular Therapeutix current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.At this time, Ocular Therapeutix's Non Currrent Assets Other are quite stable compared to the past year. Long Term Debt is expected to rise to about 78.7 M this year, although the value of Other Liabilities will most likely fall to about 18.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 59.0M | 64.3M | 83.4M | 87.6M | Total Assets | 204.9M | 149.3M | 252.1M | 126.8M |
Ocular Therapeutix balance sheet Correlations
Click cells to compare fundamentals
Ocular Therapeutix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ocular Therapeutix balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 78.7M | 261.9M | 204.9M | 149.3M | 252.1M | 126.8M | |
Short Long Term Debt Total | 59.3M | 58.4M | 59.0M | 64.3M | 83.4M | 87.6M | |
Other Current Liab | 7.6M | 12.9M | 18.5M | 22.5M | 27.1M | 28.4M | |
Total Current Liabilities | 12.0M | 26.7M | 26.3M | 31.4M | 34.9M | 36.6M | |
Total Stockholder Equity | (3.6M) | 76.1M | 88.0M | 35.4M | 91.1M | 95.7M | |
Other Liab | 12.1M | 110.3M | 33.2M | 19.8M | 22.8M | 18.3M | |
Property Plant And Equipment Net | 16.8M | 13.9M | 11.8M | 17.9M | 18.2M | 10.0M | |
Net Debt | 4.9M | (169.6M) | (105.2M) | (38.0M) | (112.4M) | (106.8M) | |
Retained Earnings | (383.6M) | (539.3M) | (545.8M) | (616.8M) | (697.6M) | (662.7M) | |
Accounts Payable | 3.3M | 2.7M | 4.6M | 5.1M | 4.4M | 3.0M | |
Cash | 54.4M | 228.1M | 164.2M | 102.3M | 195.8M | 205.6M | |
Non Current Assets Total | 18.6M | 15.7M | 13.6M | 19.7M | 19.8M | 11.8M | |
Other Assets | 1.6M | 6.6M | 1.8M | 7.6M | 1.0 | 0.95 | |
Long Term Debt | 49.3M | 41.2M | 51.4M | 54.0M | 74.9M | 78.7M | |
Cash And Short Term Investments | 54.4M | 228.1M | 164.2M | 102.3M | 195.8M | 103.6M | |
Net Receivables | 2.5M | 12.3M | 21.1M | 21.3M | 26.2M | 27.5M | |
Common Stock Shares Outstanding | 45.3M | 60.8M | 82.2M | 76.9M | 85.6M | 44.2M | |
Liabilities And Stockholders Equity | 78.7M | 261.9M | 204.9M | 149.3M | 252.1M | 126.8M | |
Non Current Liabilities Total | 70.3M | 159.1M | 90.6M | 82.5M | 126.0M | 69.6M | |
Other Current Assets | 2.2M | 8.0M | 9.5M | 4.0M | 7.9M | 8.3M | |
Other Stockholder Equity | 380.0M | 615.3M | 633.8M | 652.2M | 788.7M | 828.1M | |
Total Liab | 82.4M | 185.8M | 116.9M | 113.9M | 160.9M | 86.2M | |
Property Plant And Equipment Gross | 16.8M | 13.9M | 11.8M | 17.9M | 38.5M | 40.4M | |
Total Current Assets | 60.2M | 246.2M | 191.3M | 129.6M | 232.2M | 243.8M | |
Property Plant Equipment | 10.2M | 8.1M | 11.8M | 9.9M | 11.3M | 7.1M | |
Net Tangible Assets | (3.6M) | 76.1M | 88.0M | 35.4M | 31.8M | 40.7M | |
Retained Earnings Total Equity | (383.6M) | (539.3M) | (545.8M) | (616.8M) | (555.2M) | (527.4M) | |
Long Term Debt Total | 49.3M | 41.2M | 51.4M | 54.0M | 62.1M | 33.7M | |
Capital Surpluse | 380.0M | 615.3M | 633.8M | 652.2M | 750.0M | 424.2M | |
Inventory | 954K | 1.2M | 1.3M | 2.0M | 2.3M | 2.4M | |
Deferred Long Term Liab | 12.1M | 98.3M | 20.2M | 6.4M | 7.3M | 6.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.